Precision Medicine in Pediatric Neurooncology: A Review

Aaron Y. Mochizuki; Isaura M. Frost; Melina B. Mastrodimos; Ashley S. Plant; Anthony C. Wang; Theodore B. Moore; Robert M. Prins; Paul S. Weiss; Steven J. Jonas

doi:10.1021/acschemneuro.7b00388

Precision Medicine in Pediatric Neurooncology: A Review

Aaron Y. Mochizuki, Isaura M. Frost, Melina B. Mastrodimos, Ashley S. Plant, Anthony C. Wang, Theodore B. Moore, Robert M. Prins, Paul S. Weiss^*, Steven J. Jonas

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.

Original language	English (US)
Pages (from-to)	11-28
Number of pages	18
Journal	ACS Chemical Neuroscience
Volume	9
Issue number	1
DOIs	https://doi.org/10.1021/acschemneuro.7b00388
State	Published - Jan 17 2018

Funding

*E-mail: [email protected]. *E-mail: [email protected]. ORCID Aaron Y. Mochizuki: 0000-0003-1073-916X Isaura M. Frost: 0000-0003-2851-1008 Melina B. Mastrodimos: 0000-0002-2529-9577 Paul S. Weiss: 0000-0001-5527-6248 Steven J. Jonas: 0000-0002-8111-0249 Author Contributions The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Funding I.F. and M.M. thank the National Institutes of Health for support through UCLA Medical Scientist Training Program grant T32 GM008042. S.J.J. acknowledges the support of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Training Program through its Clinical Fellowship Training Award Program as well as Young Investigator Award funds from the Hyundai Hope on Wheels Foundation and the Alex’s Lemonade Stand Foundation for Pediatric Cancer Research. P.S.W. and S.J.J. acknowledge the David Geffen School of Medicine and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA for seed funding. Notes The authors declare no competing financial interest.

Keywords

Precision medicine
neurooncology
pediatrics
review

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acschemneuro.7b00388

Cite this

@article{1bea279a595843d8ae056566d732228b,

title = "Precision Medicine in Pediatric Neurooncology: A Review",

abstract = "Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.",

keywords = "Precision medicine, neurooncology, pediatrics, review",

author = "Mochizuki, {Aaron Y.} and Frost, {Isaura M.} and Mastrodimos, {Melina B.} and Plant, {Ashley S.} and Wang, {Anthony C.} and Moore, {Theodore B.} and Prins, {Robert M.} and Weiss, {Paul S.} and Jonas, {Steven J.}",

note = "Publisher Copyright: {\textcopyright} 2017 American Chemical Society.",

year = "2018",

month = jan,

day = "17",

doi = "10.1021/acschemneuro.7b00388",

language = "English (US)",

volume = "9",

pages = "11--28",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "1",

}

TY - JOUR

T1 - Precision Medicine in Pediatric Neurooncology

T2 - A Review

AU - Mochizuki, Aaron Y.

AU - Frost, Isaura M.

AU - Mastrodimos, Melina B.

AU - Plant, Ashley S.

AU - Wang, Anthony C.

AU - Moore, Theodore B.

AU - Prins, Robert M.

AU - Weiss, Paul S.

AU - Jonas, Steven J.

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.

AB - Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.

KW - Precision medicine

KW - neurooncology

KW - pediatrics

KW - review

UR - http://www.scopus.com/inward/record.url?scp=85040696748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040696748&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00388

DO - 10.1021/acschemneuro.7b00388

M3 - Review article

C2 - 29199818

AN - SCOPUS:85040696748

SN - 1948-7193

VL - 9

SP - 11

EP - 28

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 1

ER -

Precision Medicine in Pediatric Neurooncology: A Review

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this